Scientific Program - Epilepsy
|
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
|
| Alzheimer's disease & other Dementias | Epilepsy | Headache | History of Neurology in Poland |
| Multiple Sclerosis | Neuroimmunology | Neuropathy |
| Rehabilitation | Stroke | Wilson's disease |
| Epilepsy Section Heads: Joanna Jedrzejczak, Poland & Michael Sperling, USA |
|
|||
| 07:00-07:50 | |||
| 08:00-09:50 | EPILEPSY: DIAGNOSIS | ||
| Chairs: Eva Andermann, Canada & Ying-Jui Ho, Taiwan | |||
| 08:00-08:55 |
Can psychogenic seizures be reliably diagnosed just by observing behavior or should continuous EEG always be required?
|
||
| Capsule: |
Are the behaviors of psychogenic seizures sufficiently well understood such that the diagnosis can be made with a high degree of confidence based solely on behavioral manifestations? Given the expense and limited availability of video-EEG monitoring, and the widespread availability of video technology (through smartphones and other means), can video criteria be designated sufficient to diagnose psychogenic seizures?
|
||
| 08:00-08:10 | Host: Joanna Jedrzejczak, Poland | ||
| 08:10-08:25 |
Pro: Manjari Triapathi, India
|
||
| 08:25-08:40 | Con: Ettore Beghi, Italy | ||
| 08:40-08:55 | Discussion and Rebuttals | ||
| 08:55-09:50 |
Can we rely upon fMRI to localize verbal memory when planning epilepsy surgery?
|
||
| Capsule: | The Wada test has been used to assess risk of memory deficit when temporal lobe resection is planned to treat epilepsy. However, this test is semi-invasive and poses risk, and questions have been raised regarding its validity. fMRI techniques have significantly advanced in the past decade and are widely used to define hemisphere dominance for language. Has it reached the stage where it can be used to identify areas responsible for long-term memory so that Wada may become obsolete? | ||
| 08:55-09:05 | Host: Manjari Tripathi, India | ||
| 09:05-09:20 | Pro: William Theodore, USA | ||
| 09:20-09:35 | Con: Ilan Blatt, Israel | ||
| 09:35-09:50 | Discussion and Rebuttals | ||
| 09:50-10:10 | Coffee Break | ||
| 10:10-12:10 | EPILEPSY - THERAPY AND MANAGEMENT | ||
| Chairs: Stanislaw Jerzy Czuczwar, Poland & Andrij Dubenko, Ukraine | |||
| 10:10-11:10 |
When using combination antiepileptic drug therapy (AED), should we preferentially prescribe drugs with different mechanisms of action (A), or is the mechanism of action irrelevant to outcome (B)?
|
||
| Capsule: | AEDs have different mechanisms of action. For example, they may alter sodium channel conductance, affect GABA receptors, synaptic vesicle proteins, AMPA receptors, etc. Does the mechanism matter – should we modulate neuronal firing by targeting multiple mechanisms, or does this not matter when considering seizure control? | ||
| 10:10-10:20 |
Host: Alla Guekht, Russia
|
||
| 10:20-10:35 | A: Martin Brodie, UK | ||
| 10:35-10:50 | B: Martin Holtkamp, Germany | ||
| 10:50-11:10 | Discussion and Rebuttals | ||
| 11:10-11:40 |
Lecture: Drug Therapy for epilepsy in the elderly: Elinor Ben Menachem, Sweden
|
||
| Capsule: |
What are the special considerations that should be considered when treating elderly individuals with epilepsy? Are there differences in sensitivity to medication, side effect, and efficacy? Do we really know?
|
||
| 11:40-12:10 |
Case Studies: Michael Sperling, USA
Panelists: Manuel Toledo, Spain, Joanna Jedrzejczak, Poland, Thanos Covanis, Greece, Nandan Yardi, India |
||
| 12:10-13:10 | Industry Sponsored Symposium (Not for CME) – Hall A | ||
| 13:10-13:55 | Lunch Break & Meet the Expert sessions | ||
| 13:55-15:55 |
EPILEPSY: TREATMENT ISSUES
|
||
| Chair: Ewa Nagańska, Poland & Mira Rakacolli, Albania | |||
| 13:55-14:55 | Is there an advantage to continue trying new AED indefinitely in refractory patients? | ||
| Capsule: | Once pharmacoresistance is demonstrated, new drugs are highly unlikely to produce sustained seizure relief. However, might a new drug convey other advantages or do the potential adverse effects negate any benefit? Are there subsets of patients for whom new drug trials might help? | ||
| 13:55-14:05 |
Host: Michael Sperling, USA
|
||
| 14:05-14:20 | Yes: Martin Brodie, UK | ||
| 14:20-14:35 | No: Elinor Ben Menachem, Sweden | ||
| 14:35-14:55 | Discussion and Rebuttals | ||
| 14:55-15:55 | Do AED increase the risk of depression or suicidality? | ||
| Capsule: | People with epilepsy have increased rates of depression and suicide, and one FDA study raised possibility that drugs can increase the risk of suicide. Do drugs really increase risk of depression and suicide, and if so, which agents? | ||
| 14:55-15:05 |
Host: Martin Holtkamp, Germany
|
||
| 15:05-15:20 | Yes: Ilan Blatt, Israel | ||
| 15:20-15:35 | No: Alla Guekht, Russia | ||
| 15:35-15:55 | Discussion and Rebuttals | ||
| 15:55-16:15 |
Coffee Break
|
| 16:15-19:00 | EPILEPSY : VAGAL NERVE STIMULATION (VNS) CASE STUDIES |
| Chairs: Andrezj Rysz, Poland & Tetyana Litovchenko, Ukraine | |
| 16:15-17:10 | Should we preferentially use vagus nerve stimulation (VNS) early in patients with both seizures and depression? |
| Capsule: |
VNS has been approved for both psychiatric and epilepsy indications. There is significant co-morbidity of these conditions. VNS be considered as a therapy for patients with both conditions and used early in the course of illness?
|
| 16:15-16:25 |
Host: Zeljka Petelin Gadze, Croatia
|
| 16:25-16:40 |
Yes: Michael Sperling, USA
|
| 16:40-16:55 | No: Ivan Rektor, Czech Republic |
| 16:55-17:10 | Discussion and rebuttals |
| 17:10-19:00 |
Case Studies: Michael Sperling, USA
Panelists: Manuel Toledo, Spain, Joanna Jedrzejczak, Poland, Thanos Covanis, Greece, Nandan Yardi, India |
